Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Evaluation of the Hydatid Cyst Membrane Permeability of Albendazole and Albendazole Sulfoxide-Loaded Solid Lipid Nanoparticles

Shahrzad Soltani 1 , 2 , Abdollah Rafiei 1 , 2 , * , Zahra Ramezani 3 , Mohammad Reza Abbaspour 4 , Ali Jelowdar 2 and Mehdi Sagha Kahvaz 3
Authors Information
1 Health Reaserch Institute, Infectious and Tropical Diseases Research Center, Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Parasitology, Medical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Nanotechnology Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 2017, 12 (2); e34723
  • Published Online: January 31, 2016
  • Article Type: Research Article
  • Received: November 16, 2015
  • Revised: November 28, 2015
  • Accepted: December 6, 2015
  • DOI: 10.5812/jjnpp.34723

To Cite: Soltani S, Rafiei A, Ramezani Z, Abbaspour M R, Jelowdar A, et al. Evaluation of the Hydatid Cyst Membrane Permeability of Albendazole and Albendazole Sulfoxide-Loaded Solid Lipid Nanoparticles, Jundishapur J Nat Pharm Prod. 2017 ; 12(2):e34723. doi: 10.5812/jjnpp.34723.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis. 2009; 13(2): 125-33[DOI][PubMed]
  • 2. Eckert J, Deplazes P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev. 2004; 17(1): 107-35[PubMed]
  • 3. Smego RJ, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis. 2005; 9(2): 69-76[DOI][PubMed]
  • 4. Silva MA, Mirza DF, Bramhall SR, Mayer AD, McMaster P, Buckels JA. Treatment of hydatid disease of the liver. Evaluation of a UK experience. Dig Surg. 2004; 21(3): 227-33[DOI][PubMed]
  • 5. Tsimoyiannis EC, Siakas P, Moutesidou KJ, Karayianni M, Kontoyiannis DS, Gossios KJ. Perioperative benzimidazole therapy in human hydatid liver disease. Int Surg. 1995; 80(2): 131-3[PubMed]
  • 6. Prousalidis J, Kosmidis C, Anthimidis G, Kapoutzis K, Karamanlis E, Fachantidis E. Postoperative recurrence of cystic hydatidosis. Can J Surg. 2012; 55(1): 15-20[DOI][PubMed]
  • 7. Karabulut K, Ozbalci GS, Kesicioglu T, Tarim IA, Lap G, Kamali Polat A, et al. Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience. Ann Surg Treat Res. 2014; 87(2): 61-5[DOI][PubMed]
  • 8. Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol. 1986; 30(6): 705-8[PubMed]
  • 9. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop. 1997; 64(1-2): 79-93[PubMed]
  • 10. Eckert J, Pawlowski Z, Dar FK, Vuitton DA, Kem P, Savioli L. Medical aspects of echinococcosis. Parasitol Today. 1995; 11(8): 273-6
  • 11. Capan M, Keltner S, Thalhammer F, Winkler S, Jager W, Zeitlinger M, et al. Intra-cystic drug concentration of albendazole sulphoxide in patients with Echinococcus granulosus cysts. Am J Trop Med Hyg. 2009; 81(4): 712-3[DOI][PubMed]
  • 12. Venkatesan P. Albendazole. J Antimicrob Chemother. 1998; 41(2): 145-7[PubMed]
  • 13. Brusewitz C, Schendler A, Funke A, Wagner T, Lipp R. Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int J Pharm. 2007; 329(1-2): 173-81[DOI][PubMed]
  • 14. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010; 624: 163-75[DOI][PubMed]
  • 15. Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech. 2011; 12(2): 712-22[DOI][PubMed]
  • 16. Sinha VR, Srivastava S, Goel H, Jindal V. Solid Lipid Nanoparticles (SLN'S)-Trends and Implications in Drug Targeting. Int J of Adv in Pharmac Scie. 2010; 1(3)
  • 17. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1): 161-77[PubMed]
  • 18. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9): 1257-72[DOI][PubMed]
  • 19. Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine. 2012; 7: 1841-50[DOI][PubMed]
  • 20. Ezzati Nazhad Dolatabadi J, Valizadeh H, Hamishehkar H. Solid Lipid Nanoparticles as Efficient Drug and Gene Delivery Systems: Recent Breakthroughs. Adv Pharm Bull. 2015; 5(2): 151-9[DOI][PubMed]
  • 21. Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013; 8: 2733-44[DOI][PubMed]
  • 22. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004; 278(1): 71-7[DOI][PubMed]
  • 23. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H, Dolatabadi JE, Omidfar K. Drug targeting using solid lipid nanoparticles. Chem Phys Lipids. 2014; 181: 56-61[DOI][PubMed]
  • 24. Haverla T, Gurtler E, Takac L. [A comparative study of clinical results after 5 years of root canal treatment with calcium hydroxide and with Riebler's paste]. Cesk Stomatol. 1966; 66(4): 251-6[PubMed]
  • 25. Souto EB, Muller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008; 30(3): 157-65[DOI][PubMed]
  • 26. de Souza MC, Marchetti JM. Development of albendazole sulfoxide-loaded Eudragit microparticles: A potential strategy to improve the drug bioavailability. Adv Powder Technol. 2012; 23(6): 801-7
  • 27. Ravichandran R. In vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability. Int J Green Nanotechnol Biomed. 2010; 2(1)-53
  • 28. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J of Pharm. 2004; 272(1): 29-36
  • 29. Patel BD, Modi RV, Thakkar NA, Patel AA, Thakkar PH. Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene. J Pharm Bioallied Sci. 2012; 4-6[DOI][PubMed]
  • 30. Morris DL, Chinnery JB, Georgiou G, Stamatakis G, Golematis B. Penetration of albendazole sulphoxide into hydatid cysts. Gut. 1987; 28(1): 75-80[PubMed]
  • 31. Truong Cong T, Faivre V, Nguyen TT, Heras H, Pirot F, Walchshofer N, et al. Study on the hydatid cyst membrane: permeation of model molecules and interactions with drug-loaded nanoparticles. Int J Pharm. 2008; 353(1-2): 223-32[DOI][PubMed]
  • 32. Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials. 2003; 24(10): 1781-5
  • 33. Ibrahim WM, AlOmrani AH, Yassin AE. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. Int J Nanomedicine. 2014; 9: 129-44[DOI][PubMed]
  • 34. Yones DA, Taher GA, Ibraheim ZZ. In vitro effects of some herbs used in Egyptian traditional medicine on viability of protoscolices of hydatid cysts. Korean J Parasitol. 2011; 49(3): 255-63[DOI][PubMed]
  • 35. Verma VC, Gangwar M, Yashpal M, Nath G. Anticestodal activity of endophytic Pestalotiopsis sp. on protoscoleces of hydatid cyst Echinococcus granulosus. Biomed Res Int. 2013; 2013: 308515[DOI][PubMed]
  • 36. Skuhala T, Trkulja V, Runje M, Vukelic D, Desnica B. Albendazolesulphoxide concentrations in plasma and hydatid cyst and prediction of parasitological and clinical outcomes in patients with liver hydatidosis caused by Echinococcus granulosus. Croat Med J. 2014; 55(2): 146-55[PubMed]
  • 37. Brunetti E, Garcia HH, Junghanss T, International Ce Workshop in Lima P. Cystic echinococcosis: chronic, complex, and still neglected. PLoS Negl Trop Dis. 2011; 5(7)[DOI][PubMed]
  • 38. Smyth JD, Barrett NJ. Procedures for testing the viability of human hydatid cysts following surgical removal, especially after chemotherapy. Trans R Soc Trop Med Hyg . 1980; 74(5): 649-52
  • 39. Ceballos L, Elissondo C, Moreno L, Dopchiz M, Sanchez Bruni S, Denegri G, et al. Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations. Parasitol Res. 2008; 103(2): 355-62[DOI][PubMed]
  • 40. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T, et al. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin. J Control Rel. 2002; 85(1): 45-50
  • 41. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42(6): 463-78
  • 42. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009; 71(4): 349-58[DOI][PubMed]
  • 43. Ahmadnia S, Moazeni M, Mohammadi-Samani S, Oryan A. In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. Exp Parasitol. 2013; 135(2): 314-9[DOI][PubMed]
  • 44. Rohit B, Pal KI. A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs. Current Nanoscience. 2013; 9(2): 211-20
  • 45. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002; 242(1-2): 121-8[PubMed]
  • 46. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci. 2008; 35(5): 404-16[DOI][PubMed]
  • 47. Ezzati Nazhad Dolatabadi J, Omidi Y, Losic D. Carbon nanotubes as an advanced drug and gene delivery nanosystem. Current Nanoscience. 2011; 7(3): 297-314
  • 48. Ezzati Nazhad Dolatabadi J, Mashinchian O, Ayoubi B, Jamali AA, Mobed A, Losic D. Optical and electrochemical DNA nanobiosensors. Trac-Trend Anal Chem. 2011; (30): 459-72
  • 49. Saei AA, Dolatabadi Ezzati Nazhad J, Najafi-Marandi P, Abhari A, de la Guardia M. Electrochemical biosensors for glucose based on metal nanoparticles. TRAC-Trend Anal Chem. 2013; 42: 216-27
  • 50. Perez-Serrano J, Denegri G, Casado N, Rodriguez-Caabeiro F. In vivo effect of oral albendazole and albendazole sulphoxide on development of secondary echinococcosis in mice. Int J Parasitol. 1997; 27(11): 1341-5[PubMed]
  • 51. Lanusse CE, Virkel GL, Sanchez SF, Alvarez LI, Lifschitz AL, Imperiale F, et al. Ricobendazole kinetics and availability following subcutaneous administration of a novel injectable formulation to calves. Res Vet. 1998; 65(1): 5-10
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments